Drug Trial Radar · NCT04487275
MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code)
Last checked: Nov 19, 2026Latest source record: Jul 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 20, 2018
Primary completion
Sep 2020
Study completion Oct 2020
Sponsor
- Lead sponsor
- Ali Amini HarandiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with a diagnosis of moderate to severe traumatic brain injury (TBI) will be enrolled. Subjects will be randomly assigned to receive either MLC901 (Specified Drug Code) or placebo capsules three times per day over 6 months. Evaluation of patients will be carried out at baseline as well as at 3-month and 6-month follow-up visits. Modified Rankin Scale (mRS) and Glasgow outcome scale (GOS) will be used to examine patients. Efficacy will be evaluated by comparing these two scores between the 2 groups at follow-up visits.
Conditions
- Traumatic Brain Injury
Interventions
MLC901 or PlaceboDrug
groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- functional outcome 1Time frame: at baseline
- functional outcome 2Time frame: at 3rd month post-injury
- functional outcome 3Time frame: at 6th month post-injury
- functional outcome 4Time frame: at baseline
- functional outcome 5Time frame: at 3rd month post-injury
- functional outcome 6Time frame: at 6th month post-injury
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brain Mapping Research Center
Tehran, Iran · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.